Chinese Journal of Organic Chemistry ›› 2020, Vol. 40 ›› Issue (6): 1731-1736.DOI: 10.6023/cjoc202001034 Previous Articles     Next Articles

新型腙基取代嘧啶衍生物的合成及抗肿瘤活性评价

张洋a,b, 张路野a,b, 刘丽敏a,b, 王涛a,b, 孟娅琪a,b, 栗娜a,b, 李二冬a,b, 汪正捷a,b, 刘秀娟a,b, 郑甲信a,c, 单丽红a,b,c,d, 刘宏民a,b,c,d,e, 张秋荣a,b,c,d   

  1. a 郑州大学药学院 郑州 450001;
    b 新药创制与药物安全性评价河南省协同创新中心 郑州 450001;
    c 教育部药物关键制备技术重点实验室 郑州 450001;
    d 河南省药品质量与评价重点实验室 郑州 450001;
    e 省部共建食管癌防治国家重点实验室 郑州 450052
  • 收稿日期:2020-01-31 修回日期:2020-03-21 发布日期:2020-04-10
  • 通讯作者: 单丽红, 刘宏民, 张秋荣 E-mail:shlh@zzu.edu.cn;liuhm@zzu.edu.cn;zqr409@yeah.net
  • 基金资助:
    国家自然科学基金(No.81773562)、国家蛋白质研究项目(No.2018YFE0195100)、省部共建食管癌防治国家重点实验室资助的开放基金(No.K2020000X)资助项目.

Synthesis and Antitumor Activity Evaluation of Novel Hydrazone-Substituted Pyrimidine Derivatives

Zhang Yanga,b, Zhang Luyea,b, Liu Limina,b, Wang Taoa,b, Meng Yaqia,b, Li Naa,b, Li Erdonga,b, Wang Zhengjiea,b, Liu Xiujuana,b, Zheng Jiaxina,c, Shan Lihonga,b,c,d, Liu Hongmina,b,c,d,e, Zhang Qiuronga,b,c,d   

  1. a School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001;
    b Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou 450001;
    c Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou 450001;
    d Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001;
    e State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou 450052
  • Received:2020-01-31 Revised:2020-03-21 Published:2020-04-10
  • Supported by:
    Project supported by the National Natural Science Foundation of China (No. 81773562) and the National Key Research Program of Proteins (No. 2018YFE0195100) and the Openning Fund from State Key Laboratory of Esophageal Cancer Prevention & Treatment (No. K2020000X).

In order to find more effective antitumor drugs, a series of novel hydrazone-substituted pyrimidine derivatives were designed, synthesized and evaluated for their antitumor activity against five different human cancer cell lines including MCF-7 (human breast cancer cell), MGC-803 (human gastric cancer cell), PC-3 (human prostate cancer cell), Hela (human cervical cancer cell) and A549 (human lung cancer cell) using methyl thiazolyl tetrazolium (MTT) assay. Most of the target compounds showed moderate to potent antitumor activity against five selected cancer cell lines. Among them, 2-(prop-2-yn-1-ylthio)-4-(2-(pyridin-2-ylmethylene)-hydrazinyl)-6-(trifluoromethyl)pyrimidine (12l) displayed the most potent anti-proliferative activity against PC-3 cell line (IC50=1.37 μmol·L-1), which was significantly better than the positive control drug 5-fluorouracil. This work provided clues to discover new antitumor agents.

Key words: hydrazone, pyrimidine derivatives, synthesis, antitumor activity